Sorcin, an important gene associated with multidrug-resistance in human leukemia cells

被引:52
作者
Zhou, Y
Xu, YF
Tan, YH
Qi, J
Xiao, Y
Yang, CZ
Zhu, ZP
Xiong, DS
机构
[1] Chinese Acad Med Sci, Inst Hematol, State Key Lab Expt Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
基金
中国国家自然科学基金;
关键词
multidrug resistance; sorcin; transfection; doxorubicin; siRNA; leukemia;
D O I
10.1016/j.leukres.2005.08.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Sorcin, or soluble resistance-related calcium-binding protein, is a 22 kD calcium-binding protein initially identified in many mutlidrug resistant (MDR) cell lines. We previously observed by gene profiling that sorcin is significantly up-regulated in a doxorubicin-induced MDR leukemia cell line, K562/A02, over its parent cells. We have also demonstrated that the level of sorcin expression in leukemia patients correlates not only directly with that of the mdr1 gene, but also inversely with patients' response to chemotherapies and overall prognosis. In this report, we have carried out experiments to dissect out the contribution of sorcin by itself to drug resistant phenotype in K562 cells. Overexpression of sorcin protein by gene transfection in K562 cells resulted in increased drug resistance, from 4.1- to 22.5-fold, to a variety of chemotherapeutic agents, including doxorubicin, etoposide, homoharringtonine and vincristine. On the other hand, inhibition of sorcin expression in both MDR K562/A02 and the sorcin-transfected K562 cells with sorcin-targeting small interfering RNA led to varying extent of reversal of drug resistance. These results confirm that sorcin is an important gene associated with the development of MDR in leukemia cells. (C) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:469 / 476
页数:8
相关论文
共 26 条
  • [1] P-glycoprotein: from genomics to mechanism
    Ambudkar, SV
    Kimchi-Sarfaty, C
    Sauna, ZE
    Gottesman, MM
    [J]. ONCOGENE, 2003, 22 (47) : 7468 - 7485
  • [2] Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720
    Baer, MR
    George, SL
    Dodge, RK
    O'Loughlin, KL
    Minderman, H
    Caligiuri, MA
    Anastasi, J
    Powell, BL
    Kolitz, JE
    Schiffer, CA
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 2002, 100 (04) : 1224 - 1232
  • [3] Suppressive subtractive hybridisation reveals differential expression of serglycin, sorcin, bone marrow proteoglycan and prostate-tumour-inducing gene I (PTI-1) in drug-resistant and sensitive tumour cell lines of haematopoetic origin
    Beyer-Sehlmeyer, G
    Hiddemann, W
    Wörmann, B
    Bertram, J
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 (12) : 1735 - 1742
  • [4] Mammalian ABC transporters in health and disease
    Borst, P
    Elferink, RO
    [J]. ANNUAL REVIEW OF BIOCHEMISTRY, 2002, 71 : 537 - 592
  • [5] Drug resistance factors in acute myeloid leukemia:: a comparative analysis
    Filipits, M
    Stranzl, T
    Pohl, G
    Heinzl, H
    Jäger, U
    Geissler, K
    Fonatsch, C
    Haas, OA
    Lechner, K
    Pirker, R
    [J]. LEUKEMIA, 2000, 14 (01) : 68 - 76
  • [6] Multidrug resistance in cancer: Role of ATP-dependent transporters
    Gottesman, MM
    Fojo, T
    Bates, SE
    [J]. NATURE REVIEWS CANCER, 2002, 2 (01) : 48 - 58
  • [7] Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: A phase III trial (E2995)
    Greenberg, PL
    Lee, SJ
    Advani, R
    Tallman, MS
    Sikic, BI
    Letendre, L
    Dugan, K
    Lum, B
    Chin, DL
    Dewald, G
    Paietta, E
    Bennett, JM
    Rowe, JM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) : 1078 - 1086
  • [8] HAMADA H, 1988, CANCER RES, V48, P3173
  • [10] Hirose Masao, 2003, Journal of Medical Investigation, V50, P126